Division of Cardiovascular Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Wythenshawe Hospital, Manchester University Foundation NHS Trust, Manchester, United Kingdom.
Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, United Kingdom.
J Cardiothorac Vasc Anesth. 2022 Mar;36(3):847-854. doi: 10.1053/j.jvca.2021.06.021. Epub 2021 Jun 24.
Serum potassium levels frequently are maintained at high levels (≥4.5 mEq/L) to prevent atrial fibrillation after cardiac surgery (AFACS), with limited evidence. Before undertaking a noninferiority randomized controlled trial to investigate the noninferiority of maintaining levels ≥3.6 mEq/L compared with this strategy, the authors wanted to assess the feasibility, acceptability, and safety of recruiting for such a trial.
Pilot and feasibility study of full trial protocol.
Two university tertiary-care hospitals.
A total of 160 individuals undergoing first-time elective isolated coronary artery bypass grafting.
Randomization (1:1) to protocols aiming to maintain serum potassium at either ≥3.6 mEq/L or ≥4.5 mEq/L after arrival in the postoperative care facility and for 120 hours or until discharge from the hospital or AFACS occurred, whichever happened first.
Primary outcomes: (1) whether it was possible to recruit and randomize 160 patients for six months (estimated 20% of those eligible); (2) maintaining supplementation protocol violation rate ≤10% (defined as potassium supplementation being inappropriately administered or withheld according to treatment allocation after a serum potassium measurement); and (3) retaining 28-day follow-up rates ≥90% after surgery. Between August 2017 and April 2018, 723 patients were screened and 160 (22%) were recruited. Potassium protocol violation rate = 9.8%. Follow-up rate at 28 days = 94.3%. Data on planned outcomes for the full trial also were collected.
It is feasible to recruit and randomize patients to a study assessing the impact of maintaining serum potassium concentrations at either ≥3.6 mEq/L or ≥4.5 mEq/L on the incidence of AFACS.
心脏手术后(AFACS)常将血清钾水平维持在较高水平(≥4.5 mEq/L)以预防心房颤动,但证据有限。在进行一项非劣效性随机对照试验以研究将水平维持在≥3.6 mEq/L 与该策略相比的非劣效性之前,作者希望评估招募此类试验的可行性、可接受性和安全性。
全试验方案的试点和可行性研究。
两所大学三级保健医院。
总共 160 名接受首次择期单纯冠状动脉旁路移植术的个体。
随机(1:1)分组,旨在在到达术后护理病房后将血清钾水平维持在≥3.6 mEq/L 或≥4.5 mEq/L 并持续 120 小时或直至出院或发生 AFACS,以先发生者为准。
主要结局:(1)是否有可能在六个月内招募和随机分配 160 名患者(估计符合条件者的 20%);(2)维持补充方案违反率≤10%(定义为根据治疗分配在进行血清钾测量后不恰当地给予或延迟给予钾补充剂);(3)手术后 28 天的随访率≥90%。2017 年 8 月至 2018 年 4 月,共筛选了 723 名患者,其中 160 名(22%)入选。钾方案违反率为 9.8%。28 天随访率为 94.3%。还收集了全试验计划结局的数据。
招募和随机分配患者参加评估将血清钾浓度维持在≥3.6 mEq/L 或≥4.5 mEq/L 对心房颤动发生率影响的研究是可行的。